Oncología Traslacional
ONCTRAS
Hospital Universitario Reina Sofia
Córdoba, EspañaPublikationen in Zusammenarbeit mit Forschern von Hospital Universitario Reina Sofia (27)
2024
-
Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/ MINOVA Study)
Clinical Cancer Research, Vol. 30, Núm. 1, pp. 176-186
-
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial
Annals of Oncology
-
Retrospective multicenter study of elderly patients with platinum-sensitive relapsed ovarian cancer treated with trabectedin and pegylated liposomal doxorubicin (pld) in a real-world setting: a geico study
BMC Cancer, Vol. 24, Núm. 1
-
Tolerability of the niraparib individualized starting dose in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy
European Journal of Cancer, Vol. 208
2023
-
Clinical and molecular signature of survival and resistance to olaparib plus pegylated liposomal doxorubicin in platinum-resistant ovarian cancer: A stratified analysis from the phase II clinical trial ROLANDO, GEICO-1601
International Journal of Gynecological Cancer, Vol. 33, Núm. 6, pp. 929-936
-
Controversies in the treatment of advanced ovarian cancer in the PARP inhibitors era: a Delphi consensus
Journal of gynecologic oncology, Vol. 34, Núm. 5, pp. e57
-
Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer
Gynecologic Oncology, Vol. 170, pp. 300-308
2022
-
Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial
European Journal of Cancer, Vol. 174, pp. 221-231
-
Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis
Gynecologic Oncology, Vol. 164, Núm. 3, pp. 498-504
-
Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study
Cancers, Vol. 14, Núm. 4
-
Prospective Real-World Gynaecological Cancer Clinical Registry with Associated Biospecimens: A Collaborative Model to Promote Translational Research between GEICO and the Spanish Biobank Network
Cancers, Vol. 14, Núm. 8
2021
-
Management of advanced ovarian cancer in Spain: an expert Delphi consensus
Journal of Ovarian Research, Vol. 14, Núm. 1
-
Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study)
ESMO open, Vol. 6, Núm. 4, pp. 100212
-
SEOM clinical guideline in ovarian cancer (2020)
Clinical and Translational Oncology, Vol. 23, Núm. 5, pp. 961-968
2020
-
Niraparib in Patients With Newly Diagnosed Advanced Ovarian Cancer
Obstetrical and Gynecological Survey
2019
-
Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer
International Journal of Gynecological Cancer, Vol. 29, Núm. 6, pp. 1050-1056
-
Multicenter retrospective study to evaluate the impact of trabectedin plus pegylated liposomal doxorubicin on the subsequent treatment in women with recurrent, platinum-sensitive ovarian cancer
Anti-Cancer Drugs, Vol. 30, Núm. 6, pp. 628-635
-
Niraparib in patients with newly diagnosed advanced ovarian cancer
New England Journal of Medicine, Vol. 381, Núm. 25, pp. 2391-2402
2017
-
A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM)
Clinical and Translational Oncology, Vol. 19, Núm. 5, pp. 616-624
2016
-
Nab-Paclitaxel in metastatic breast cancer: Defining the best patient profile
Current Cancer Drug Targets, Vol. 16, Núm. 5, pp. 415-428